Effect of obesity on platelet reactivity and response to low-dose aspirin

Preventive Cardiology

Volumn 13, Issue 2, 2010, Pages 56-62

  Bordeaux, Bryan C ^a   Qayyum, Rehan ^b   Yanek, Lisa R ^b   Vaidya, Dhananjay ^b   Becker, Lewis C ^c   Faraday, Nauder ^d   Becker, Diane M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Divisions of General Internal Medicine   (United States)

^c Department of Cardiology ^*  (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; CYCLOOXYGENASE 1;

ADULT; ARTICLE; BIOACCUMULATION; BLOOD CLOTTING PARAMETERS; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG URINE LEVEL; FAMILY HISTORY; FEMALE; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COLLAGEN; DRUG RESISTANCE; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TIME FACTORS;

EID: 77952037162     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2009.00058.x     Document Type: Article

References (30)

1. Mora S, Yanek LR, Moy TF. Interaction of body mass index and framingham risk score in predicting incident coronary disease in families. Circulation 2005, 111:1871-1876.
2. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
3. Grundy SM, Brewer HB, Cleeman JI. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
4. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005, 118:978-980.
5. Poirier P, Giles TD, Bray GA. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113:898-918.
6. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002, 136:157-160.
7. Becker DM, Yook RM, Moy TF. Markedly high prevalence of coronary risk factors in apparently healthy African-American and white siblings of persons with premature coronary heart disease. Am J Cardiol 1998, 82:1046-1051.
8. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353:2373-2383.
9. Gonzalez-Conejero R, Rivera J, Corral J. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005, 36:276-280.
10. Faraday N, Becker DM, Yanek LR. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006, 98:774-779.
11. Frelinger AL, Furman MI, Linden MD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006, 113:2888-2896.
12. Ohmori T, Yatomi Y, Nonaka T. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006, 4:1271-1278.
13. Gum PA, Kottke-Marchant K, Welsh PA. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965.
14. Eikelboom JW, Hirsh J, Weitz JI. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650-1655.
15. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 136:161-172.
16. Becker DM, Segal J, Vaidya D. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006, 295:1420-1427.
17. Chobanian AV, Bakris GL, Black HR. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
19. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
20. Pereira MA, FitzerGerald SJ, Gregg EW. A collection of Physical Activity Questionnaires for health-related research. Med Sci Sports Exerc 1997, 29(suppl 6):S1-S205.
21. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs 2000, 15:90-96.
22. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr 1998, 68:899-917.
23. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-130.
24. Cox D, Maree AO, Dooley M. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006, 37:2153-2158.
25. Tamminen M, Lassila R, Westerbacka J. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003, 27:907-911.
26. Maree AO, Curtin RJ, Dooley M. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005, 46:1258-1263.
27. Davi G, Guagnano MT, Ciabattoni G. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002, 288:2008-2014.
28. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006, 189:47-60.
29. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999, 48:426-429.
30. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001, 108:1533-1540.